Medical/Pharmaceuticals News Releases APAC-PR Newswire APAC

NaviFUS highlights clinical trial data and device capabilities at virtual International Focused Ultrasound Symposium

TAIPEI, Nov. 27, 2020 /PRNewswire/ -- The 7th International Focused Ultrasound Symposium organized by the U.S. Focused Ultrasound Foundation took place from 11/9 to 11/13 in virtual format this year due to the Covid-19 epidemic. During the 5-day conference, participants presented and exchanged in...

2020-11-27 12:21

European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations

DARMSTADT, Germany, Nov. 27, 2020 /PRNewswire/ -- Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) ...

2020-11-27 08:42 370

Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis

LONDON, Nov. 27, 2020 /PRNewswire/ -- Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis. The first-in-human trial initiated last year in heal...

2020-11-27 08:39 341

Nose Filler Injection Can Cause Vision Loss When Injected With Poor Injection Techniques & Without Understanding Of Facial Anatomy, Dr Ivan Puah Warns

SINGAPORE, Nov. 26, 2020 /PRNewswire/ -- Dermal fillers using hyaluronic acid is one of the common types of soft-tissue augmentation used inSingapore for nose enhancement. Medical Director of Amaris B. Clinic, DrIvan Puah warns that when inexperienced medical injectors or non-medical professional...

2020-11-26 22:07 816

Nose Filler Injection Can Cause Vision Loss When Injected With Poor Injection Techniques & Without Understanding Of Facial Anatomy, Dr Ivan Puah Warns

Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines with Joint Commitment to Raising Mental Health Awareness

* Luye Pharma grants Distriphil exclusive distribution and marketing rights for Seroquel® and Seroquel XR® in the Philippines * Two companies pledge to make joint effort to raise awareness of mental health issues as part of the "We Care About Mental Health" initiative SHANGHAI, Nov. 26, 2020 ...

2020-11-26 16:44 892

Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines with Joint Commitment to Raising Mental Health Awareness

Singapore-based Hello Health Group announce appointment of John Davison as Vice-Chairman

SINGAPORE, Nov. 26, 2020 /PRNewswire/ -- Hello Health Group, a leading Digital Health company inAsia focusing on the development of health and wellness information platforms and services in local languages for consumers and patients, is excited to announce the appointment ofJohn Davison as Vice-...

2020-11-26 16:40 930

Interim report, May-October 2020/21

STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- In Elekta's second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances. We also improved margins and stabilized cash flow. The launch of our new Harmony...

2020-11-26 15:01 2286

Gustaf Salford appointed Elekta CEO by Board of Directors

STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that Gustaf Salford has been appointed to the role of President and CEO, effective immediately. He has been Acting CEO since earlyJune 2020. Elekta's Board of Directors carried out an extensive search process, with the c...

2020-11-26 14:59 1506

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...

2020-11-26 14:04 1213

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematolog...

2020-11-26 10:32 755

Sirtex Medical and China Grand Pharmaceutical announce SIR-Spheres® Y-90 resin microspheres milestone

SIR-Spheres® new drug application is accepted by the National Medical Products Administration of China WOBURN, Mass., Nov. 26, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex with the support of its shareh...

2020-11-26 01:17 858

RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

LUND, Sweden, Nov. 25, 2020 /PRNewswire/ -- RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to the company's drug candidate, RV001. Fast Track Designation is granted to investigational drugs for expedited review by the FDA, to facilitate ...

2020-11-25 16:06 656

Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

SUZHOU, China and ROCKVILLE, Md., Nov. 25, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a Phase Ib/II clinical ...

2020-11-25 08:27 711

MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients

NYON, Switzerland, Nov. 25, 2020 /PRNewswire/ -- MedAlliance has announced completion of patient enrolment in theISABELLA Clinical Trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of dysfunctional AV fistulas in end-stage renal failure patients undergoing hemodialysis. SE...

2020-11-25 08:00 731

MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients

Janssen Korea Ltd. and Johnson & Johnson Innovation Announce Awardees of the Seoul Innovation QuickFire Challenge on Healthcare for the New Normal in Collaboration with the Seoul Metropolitan Government and Korea Health Industry Development Institute

- Awardees DC Medical and deepmedi recognized for pioneering efforts leveraging data and health technologies to advance potentially life-saving ideas aimed at improving patient care during the COVID-19 pandemic and beyond. SEOUL, South Korea, Nov. 25, 2020 /PRNewswire/ -- Janssen Korea Ltd. and ...

2020-11-25 07:00 1054

RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences

TEL AVIV, Israel and RALEIGH, N.C., Nov. 25, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present and participate at the following virtual conferen...

2020-11-25 07:00 1202

Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

BARCELONA, Spain, Nov. 25, 2020 /PRNewswire/ -- AlmirallShare , the open innovation platform of Almirall, S.A. (ALM), announces two new collaborations with theUniversity of South Australia and the Fundació Institut de Recerca de ...

2020-11-25 06:00 2358

Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2021

HONG KONG, Nov. 25, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for...

2020-11-25 05:16 4319

The cost of one dose of the Sputnik V vaccine will be less than $10 for international markets

RDIF continues expanding existing agreements with international manufacturing partners to produce the vaccine for more than 500 million people in 2021 MOSCOW, Nov. 25, 2020 * The cost of one dose of the Sputnik V vaccine for international markets will be less than$10. Sputnik V is a two dose ...

2020-11-25 04:38 676

Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose

MOSCOW, Nov. 24, 2020 /PRNewswire/ -- * The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose). * Calculation was based on the analysis of data on volunteers (n = 18,794) ...

2020-11-24 22:14 718